$MLAB

Archbold Brian David sold $225K of MLAB

Archbold Brian David (SVP Operations) sold 2,516 shares of MESA LABORATORIES INC /CO/ (MLAB) at $89.50 ($0.23M total) on 2026-06-22.

Original reporting
SEC EDGAR · Archbold Brian David
Published Jun 23, 2026, 5:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MLAB
Neutral
medium confidence
Mentioned
$MLAB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MLABNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings; it does not include any operational or financial update.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale alone is unlikely to change valuation materially.

03

What to watch

Insider sales are more informative when aggregated over time (multiple officers, repeated sells) or when accompanied by other disclosures (earnings misses, guidance cuts, litigation).

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-23; sale executed 2026-06-22.

Background

The article is an SEC Form 4 insider transaction disclosure for MESA LABORATORIES INC (MLAB).

Company-level read

Ticker impact

$MLABNeutralMedium confidence
Context

SEC Form 4 shows MESA LABORATORIES SVP Operations Archbold sold 2,516 shares at $89.5020 on 2026-06-22.

Expected impact

Limited near-term impact; any effect is likely short-lived unless repeated or paired with other negative disclosures.

Evidence & confidence

The filing is a disclosed sale (not a buy), but it provides no new company fundamentals, guidance, or regulatory/contract event.

Market effects

No sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The sale may be driven by diversification, taxes, or pre-existing compensation plans rather than a bearish view; the article notes no 10b5-1 plan but that still doesn’t imply negative fundamentals.

Key entities

  • MLAB

    MESA LABORATORIES INC /CO/; subject of the Form 4 insider sale disclosure.

  • Archbold Brian David

    SVP Operations who sold 2,516 shares at $89.5020 on 2026-06-22.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MLABMedAI 8/10

Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million…

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth The Restructuring Program focuses Clinical Genomics on profitability and adds resources in

$MLABMedAI 8/10

Mesa Laboratories (MLAB) Q1 2027 Earnings Call Transcript

Mesa Laboratories (MLAB) reported Q1 FY2027 revenues of $60.1 million, up 1% year over year, with core organic growth of 0.4%. Adjusted operating income was $15.4 million, up 19.5%, and gross margin rose to 64.9%. Net leverage fell to 1.85x after $8.7 million debt repayment. SDC revenue was $24.5 million, down 3.6% organically.

$MLABMed

Mesa Labs Announces First Quarter Results

MESA LABORATORIES INC /CO/ (MLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Mesa Labs Announces First Quarter Results Lakewood, Colorado , August 10, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announc

$MLABHighAI 9/10

Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

Mesa Laboratories (NASDAQ:MLAB) reported 4Q26 revenues up 2.6% to $63.7M and FY26 revenues up 3.4% to $249.1M. Operating income rose 87% to $2.75M in 4Q26 and 13.3% to $18.5M in FY26. Non-GAAP AOI excluding unusual items increased 49.2% (4Q26) and 11.9% (FY26); FY26 free cash flow was $39.6M, used mainly to repay $14.7M debt, reducing net leverage to 2.11.